Furthermore, the elimination of Bcl‐1, associated with increased AD pathology, along with the targeted reduction of Atg7 in an APP/PS1 mice model of AD, led to an increased release of Aβ, which in turn encourages the creation of extracellular Aβ. Here, APP is linked to Alzheimer disease.